AI Insight
Researchers at City of Hope have developed a novel microbiome therapy consisting of 16 carefully selected beneficial bacteria to prevent bloodstream infections in patients undergoing donor stem cell transplants for blood cancers. This first-of-its-kind approach aims to restore healthy gut microbiome balance and combat harmful pathogens that commonly cause life-threatening infections in immunocompromised transplant recipients. The therapy represents an early-stage clinical trial exploring whether targeted bacterial consortia can reduce infection risk during the vulnerable post-transplant period.
Why it matters
Bloodstream infections are a major cause of mortality in stem cell transplant patients whose immune systems are severely weakened during treatment. A successful microbiome-based preventive therapy could reduce reliance on antibiotics, decrease transplant-related deaths, and improve outcomes for blood cancer patients requiring these life-saving procedures.
Understand the Science
Researchers at City of Hope and collaborators have pioneered a new approach to preventing dangerous bloodstream infections in patients receiving donor stem cell transplants for blood cancers. The first-of-its-kind therapy delivers 16 carefully selected beneficial bacteria designed to restore the microbiome and fight harmful pathogens.
Source: Microbiome therapy shows promise for preventing deadly bloodstream infections in early trial